A Patient with HCV Infection and a Sustained Virological Response to Direct-acting Antiviral Treatment Who Developed Inclusion Body Myositis

Intern Med. 2018 Sep 1;57(17):2511-2515. doi: 10.2169/internalmedicine.0585-17. Epub 2018 Mar 30.

Abstract

We report the case of a 75-year-old woman who was found to have hepatitis C virus (HCV) infection in 1987. Before treatment in 2016, she was found to have mixed cryoglobulinemia (MC). Direct-acting antiviral (DAA) treatment produced a sustained virological response 12 (SVR12). She noticed gradual muscle weakness in 2015 and the gradual development of dysarthria and dysphagia in 2017. We performed a muscle biopsy that showed inclusion body myositis (IBM). To the best of our knowledge, this is first case of a patient with HCV infection, MC, and IBM, in which MC and IBM did not improve after an SVR12 was obtained by DAA treatment.

Keywords: direct-acting antiviral; hepatitis C virus; inclusion body myositis; mixed cryoglobulinemia; sustained virological response.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Anilides / therapeutic use
  • Antiviral Agents / therapeutic use*
  • Carbamates / therapeutic use
  • Cryoglobulinemia / complications*
  • Cryoglobulinemia / diagnosis
  • Cryoglobulinemia / drug therapy
  • Cyclopropanes
  • Female
  • Hepatitis C, Chronic / complications*
  • Hepatitis C, Chronic / diagnosis
  • Hepatitis C, Chronic / drug therapy*
  • Humans
  • Lactams, Macrocyclic
  • Macrocyclic Compounds / therapeutic use
  • Myositis, Inclusion Body / complications*
  • Myositis, Inclusion Body / diagnosis
  • Myositis, Inclusion Body / drug therapy
  • Proline / analogs & derivatives
  • Ritonavir / therapeutic use
  • Sulfonamides
  • Sustained Virologic Response
  • Valine

Substances

  • Anilides
  • Antiviral Agents
  • Carbamates
  • Cyclopropanes
  • Lactams, Macrocyclic
  • Macrocyclic Compounds
  • Sulfonamides
  • ombitasvir
  • Proline
  • Valine
  • Ritonavir
  • paritaprevir